{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:58:00Z","timestamp":1789747080207,"version":"4.0.1"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002713","name":"Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023673","name":"Imam Mohammed Ibn Saud Islamic University Deanship of Scientific Research","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}],"id":[{"id":"10.13039\/501100023673","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109097","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:35:44Z","timestamp":1760196944000},"page":"109097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation"],"prefix":"10.1016","volume":"166","author":[{"given":"Mokhtar","family":"Rejili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Sadique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Haouala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumna","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudasir","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109097_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.109097_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0015","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.109097_bb0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian Cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.bioorg.2025.109097_bb0025","first-page":"0371","article-title":"Progesterone enhances Niraparib efficacy in ovarian Cancer by promoting Palmitoleic-acid-mediated Ferroptosis","volume":"7","author":"Wu","year":"2024","journal-title":"Research (Washington, DC)."},{"key":"10.1016\/j.bioorg.2025.109097_bb0030","first-page":"318","article-title":"The cytotoxicity effect of recombinant arazyme on breast and ovarian cancer cells","volume":"7","author":"Koosha","year":"2022","journal-title":"Eurasian J. Med. Oncol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0035","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.24976\/Discov.Med.202436191.224","article-title":"Role of KIF20A depletion in inhibiting ovarian Cancer progression: insights from PTEN and M2 macrophage polarization","volume":"36","author":"Wang","year":"2024","journal-title":"Discov. Med."},{"key":"10.1016\/j.bioorg.2025.109097_bb0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13273-023-00360-3","article-title":"YTHDC1 inhibits cell proliferation and angiogenesis in cervical cancer by regulating m6A modification of SOCS4 mRNA","volume":"20","author":"Chen","year":"2024","journal-title":"Mol. Cellular Toxicol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109097_bb0050","doi-asserted-by":"crossref","DOI":"10.3788\/COL202018.051701","article-title":"Detection of breast cancer based on novel porous silicon Bragg reflector surface-enhanced Raman spectroscopy-active structure","volume":"18","author":"Ma","year":"2020","journal-title":"Chin. Opt. Lett."},{"key":"10.1016\/j.bioorg.2025.109097_bb0055","first-page":"25","article-title":"PROTACs in ovarian Cancer: current advancements and future perspectives","author":"Vorderbruggen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109097_bb0060","first-page":"17","article-title":"PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation","author":"Syahputra","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109097_bb0065","first-page":"5","article-title":"Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells","author":"Testa","year":"2018","journal-title":"Medicines (Basel, Switzerland)s"},{"key":"10.1016\/j.bioorg.2025.109097_bb0070","article-title":"Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness","volume":"299","author":"Zhang","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.851065","article-title":"FAK PROTAC inhibits ovarian tumor growth and metastasis by disrupting kinase dependent and independent pathways","volume":"12","author":"Huo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0080","article-title":"Recent advances in PROTAC technology toward new therapeutic modalities","volume":"19","author":"Yokoo","year":"2022","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2025.109097_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40259-022-00551-9","article-title":"PROTACs: current trends in protein degradation by proteolysis-targeting chimeras","volume":"36","author":"Madan","year":"2022","journal-title":"Biodrugs"},{"key":"10.1016\/j.bioorg.2025.109097_bb0095","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4155\/fmc-2022-0149","article-title":"Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention","volume":"14","author":"Singh","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0100","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2025.109097_bb0105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/acs.biochem.2c00310","article-title":"Targeted protein degradation via lysosomes","volume":"62","author":"Paudel","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2025.109097_bb0110","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41598-024-52413-9","article-title":"Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109097_bb0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1039\/D3CB00105A","article-title":"PROTAC chemical probes for histone deacetylase enzymes","volume":"4","author":"Patel","year":"2023","journal-title":"RSC chemical biology."},{"key":"10.1016\/j.bioorg.2025.109097_bb0120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acs.bioconjchem.4c00253","article-title":"Targeted protein degradation (TPD) for immunotherapy: understanding proteolysis targeting chimera-driven ubiquitin-proteasome interactions","volume":"35","author":"Kamaraj","year":"2024","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0125","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2174\/1568026621666211015092047","article-title":"Advances in the design and development of PROTAC-mediated HDAC degradation","volume":"22","author":"Rodrigues","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0130","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.109097_bb0135","doi-asserted-by":"crossref","first-page":"13879","DOI":"10.1039\/D4CC05138F","article-title":"Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3","volume":"60","author":"Pavan","year":"2024","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bioorg.2025.109097_bb0140","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/s41467-025-61112-6","article-title":"Small-molecule-induced liquid-liquid phase separation suppresses the carcinogenesis of \u03b2-catenin","volume":"16","author":"Yan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109097_bb0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109097_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.133680","article-title":"Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment","volume":"275","author":"Fan","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0155","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109097_bb0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114211","article-title":"Design and pharmaceutical applications of proteolysis-targeting chimeric molecules","volume":"182","author":"Liang","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70009","article-title":"CRBN-PROTACs in Cancer therapy: from mechanistic insights to clinical applications","volume":"104","author":"Thapa","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.109097_bb0175","article-title":"From foe to friend: rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor","volume":"15","author":"You","year":"2025","journal-title":"J. Pharmaceut. Anal."},{"key":"10.1016\/j.bioorg.2025.109097_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105848","article-title":"Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery","volume":"125","author":"Xi","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0185","first-page":"e59472","article-title":"Chemical inactivation of the E3 ubiquitin ligase Cereblon by Pomalidomide-based Homo-PROTACs","volume":"147","author":"Lindner","year":"2019","journal-title":"J. Vis. Exp.: JoVE"},{"key":"10.1016\/j.bioorg.2025.109097_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105109","article-title":"PROTACs technology for targeting non-oncoproteins: advances and perspectives","volume":"114","author":"Wang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0195","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2025.109097_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf6249","article-title":"Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras","volume":"382","author":"Ahn","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.109097_bb0205","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07089-6","article-title":"Targeted protein degradation via intramolecular bivalent glues","volume":"627","author":"Hsia","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109097_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2022.08.004","article-title":"Target protein localization and its impact on PROTAC-mediated degradation","volume":"29","author":"Simpson","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0220","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","article-title":"Targeted protein degrader development for cancer: advances, challenges, and opportunities","volume":"44","author":"Fang","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2025.109097_bb0225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/imm.13793","article-title":"Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy","volume":"173","author":"Wang","year":"2024","journal-title":"Immunology"},{"key":"10.1016\/j.bioorg.2025.109097_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115447","article-title":"Proteolysis-targeting chimeras in biotherapeutics: current trends and future applications","volume":"257","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0235","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1021\/jacs.3c13646","article-title":"Structurally specific Z-DNA proteolysis targeting chimera enables targeted degradation of adenosine deaminase acting on RNA 1","volume":"146","author":"Wang","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109097_bb0240","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/acs.jmedchem.2c01555","article-title":"Advancing strategies for proteolysis-targeting chimera design","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0245","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2020.12.003","article-title":"The rise of covalent proteolysis targeting chimeras","volume":"62","author":"Gabizon","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0250","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4155\/fmc-2018-0557","article-title":"Proteolysis-targeting chimeras for targeting protein for degradation","volume":"11","author":"Qi","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0255","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1158\/0008-5472.CAN-21-0030","article-title":"Targeting an inducible SALL4-mediated Cancer vulnerability with sequential therapy","volume":"81","author":"Yang","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109097_bb0260","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.bioorg.2025.109097_bb0265","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-021-01424-5","article-title":"The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis","volume":"20","author":"Drumond-Bock","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.109097_bb0270","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2020.01.038","article-title":"CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes","volume":"157","author":"Petersen","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13046-019-1387-5","article-title":"Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer","volume":"38","author":"Noblejas-L\u00f3pez","year":"2019","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"key":"10.1016\/j.bioorg.2025.109097_bb0280","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1021\/jacs.1c00451","article-title":"Cancer selective target degradation by folate-caged PROTACs","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109097_bb0285","first-page":"522","article-title":"Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers","volume":"3","author":"Shackelford","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0290","doi-asserted-by":"crossref","first-page":"12657","DOI":"10.1038\/srep12657","article-title":"Discovery of novel inhibitors and fluorescent probe targeting NAMPT","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109097_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129393","article-title":"Discovery of potent NAMPT-targeting PROTACs using FK866 as the warhead","volume":"92","author":"Zhang","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109097_bb0300","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.apsb.2021.12.017","article-title":"NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.109097_bb0305","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","article-title":"Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16","volume":"15","author":"Zhang","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0310","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance Defactinib versus placebo after first-line chemotherapy in patients with Merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0315","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing kinase-independent functions of Fak via PROTAC-mediated degradation","volume":"140","author":"Cromm","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109097_bb0320","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1101\/gad.284166.116","article-title":"HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer","volume":"30","author":"Fan","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2025.109097_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/147601","article-title":"Nonselective mevalonate kinase inhibitor as a novel class of antibacterial agents","volume":"2015","author":"Gharehbeglou","year":"2015","journal-title":"Cholesterol"},{"key":"10.1016\/j.bioorg.2025.109097_bb0330","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00726-011-1008-x","article-title":"TG2, a novel extracellular protein with multiple functions","volume":"42","author":"Wang","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/j.bioorg.2025.109097_bb0335","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1158\/0008-5472.CAN-07-6130","article-title":"Clinical and biological significance of tissue transglutaminase in ovarian carcinoma","volume":"68","author":"Hwang","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109097_bb0340","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1158\/0008-5472.CAN-09-1257","article-title":"Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase","volume":"69","author":"Shao","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109097_bb0345","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1021\/acs.jmedchem.2c01859","article-title":"Discovery and characterization of PROTACs targeting tissue transglutaminase (TG2)","volume":"66","author":"Valdivia","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0350","first-page":"24","article-title":"Estrogens, estrogen receptors and tumor microenvironment in ovarian Cancer","author":"Kozie\u0142","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109097_bb0355","doi-asserted-by":"crossref","first-page":"57","DOI":"10.15212\/AMM-2024-0006","article-title":"New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives","volume":"3","author":"Min","year":"2024","journal-title":"Acta Materia Medica."},{"key":"10.1016\/j.bioorg.2025.109097_bb0360","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future oncology (London, England)."},{"key":"10.1016\/j.bioorg.2025.109097_bb0365","first-page":"17","article-title":"Orally bioavailable proteolysis-targeting chimeras: an innovative approach in the golden era of discovering small-molecule cancer drugs","author":"Rej","year":"2024","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10.1016\/j.bioorg.2025.109097_bb0370","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/endrev\/bnad018","article-title":"Reevaluating the role of progesterone in ovarian Cancer: is progesterone always protective?","volume":"44","author":"Mauro","year":"2023","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bioorg.2025.109097_bb0375","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-6577","article-title":"Chemoproteomic evaluation of PROTACs targeting estrogen receptor alpha for ER+ breast cancer","volume":"84","author":"Sandusky","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109097_bb0380","first-page":"2420","article-title":"Overexpression of HER-2 in ovarian carcinomas","volume":"61","author":"Hellstr\u00f6m","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109097_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114775","article-title":"Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers","volume":"244","author":"Hu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0390","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1021\/acs.jmedchem.3c00013","article-title":"Persistent degradation of HER2 protein by hybrid nanoPROTAC for programmed cell death","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0395","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/s42003-024-07439-0","article-title":"Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors","volume":"7","author":"Tolosa","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0400","doi-asserted-by":"crossref","first-page":"15885","DOI":"10.3390\/ijms140815885","article-title":"Angiogenesis-related pathways in the pathogenesis of ovarian cancer","volume":"14","author":"Gavalas","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109097_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114821","article-title":"Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer","volume":"244","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0410","doi-asserted-by":"crossref","first-page":"33384","DOI":"10.1039\/D4RA05244G","article-title":"Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents","volume":"14","author":"Chaudhari","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109097_bb0415","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0420","doi-asserted-by":"crossref","first-page":"12800","DOI":"10.1021\/acs.jmedchem.5c00679","article-title":"Discovery and optimization of potent PROTAC degraders of phosphoinositide 3-kinase with significant in vivo anticancer efficacy","volume":"68","author":"Peng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0425","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1039\/D3SC04629J","article-title":"A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3K\u03b1","volume":"15","author":"Jauslin","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2025.109097_bb0430","first-page":"530","article-title":"Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer","volume":"11","author":"Bauer","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109097_bb0435","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.2174\/0929867329666220211091806","article-title":"Recent developments in targeting Bromodomain and extra terminal domain proteins for Cancer therapeutics","volume":"29","author":"Cai","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0440","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202500102","article-title":"Ternary complex modeling, induced fit docking and molecular dynamics simulations as a successful approach for the design of VHL-mediated PROTACs targeting the kinase FLT3","volume":"358","author":"Nassar","year":"2025","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2025.109097_bb0445","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/ijgc-00009577-200607000-00007","article-title":"Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property","volume":"16","author":"Jandu","year":"2006","journal-title":"Int. J. Gynecol. Cancer\u202f: Off. J. Int. Gynecol. Cancer Soc."},{"key":"10.1016\/j.bioorg.2025.109097_bb0450","first-page":"24","article-title":"Adipocyte microenvironment in ovarian Cancer: a critical contributor?","author":"Duarte Mendes","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109097_bb0455","first-page":"C721","article-title":"Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment","volume":"325","author":"Jazwinska","year":"2023","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.bioorg.2025.109097_bb0460","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1021\/acs.chemrev.2c00915","article-title":"The Dawn of a new era: targeting the \u201cUndruggables\u201d with antibody-based therapeutics","volume":"123","author":"Qian","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2025.109097_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156001","article-title":"Exploiting E3 ligases for lung cancer therapy: the promise of DCAF-PROTACs","volume":"270","author":"Hussain","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bioorg.2025.109097_bb0470","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.2147\/IJN.S448684","article-title":"Nano-proteolysis targeting chimeras (Nano-PROTACs) in Cancer therapy","volume":"19","author":"Song","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioorg.2025.109097_bb0475","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.7150\/thno.113356","article-title":"Challenges and opportunities for the diverse substrates of SPOP E3 ubiquitin ligase in cancer","volume":"15","author":"Yang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2025.109097_bb0480","doi-asserted-by":"crossref","first-page":"5634724","DOI":"10.1155\/2022\/5634724","article-title":"Mitochondrial dysfunction pathway alterations offer potential biomarkers and therapeutic targets for ovarian Cancer","volume":"2022","author":"Shen","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2025.109097_bb0485","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2025.109097_bb0490","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/jacs.9b12718","article-title":"Optical control of small molecule-induced protein degradation","volume":"142","author":"Naro","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109097_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108725","article-title":"Powering up targeted protein degradation through active and passive tumour-targeting strategies: current and future scopes","volume":"263","author":"Venkatesan","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109097_bb0500","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1021\/acs.jmedchem.4c02637","article-title":"Analyzing the linker structure of PROTACs throughout the induction process: computational insights","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0505","doi-asserted-by":"crossref","first-page":"9842","DOI":"10.1021\/acs.jmedchem.3c02340","article-title":"Novel amphiphilic PROTAC with enhanced pharmacokinetic properties for ALK protein degradation","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16050674","article-title":"Novel drug delivery systems: an important direction for drug innovation Research and Development","volume":"16","author":"Chen","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109097_bb0515","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1535-7163.MCT-10-0172","article-title":"Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer","volume":"9","author":"Bisht","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.109097_bb0520","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-025-03917-0","article-title":"Physiological considerations and delivery strategies for targeting tumors through intraperitoneal delivery","author":"Jony","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2025.109097_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/marc.202401051","article-title":"Integrating proteolysis-targeting chimeras (PROTACs) with delivery Systems for More Efficient and Precise Targeted Protein Degradation","volume":"46","author":"Lin","year":"2025","journal-title":"Macromol. Rapid Commun."},{"key":"10.1016\/j.bioorg.2025.109097_bb0530","article-title":"Glutathione-scavenging nanoparticle-mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.bioorg.2025.109097_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2025.103851","article-title":"PARP1-PROTACs providing novel opportunities in precision oncology by targeting DNA damage response","volume":"150","author":"Hussain","year":"2025","journal-title":"DNA Repair"},{"key":"10.1016\/j.bioorg.2025.109097_bb0540","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.109097_bb0545","first-page":"15","article-title":"PARP inhibitors in breast and ovarian Cancer","author":"Wang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.109097_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16111962","article-title":"The prognostic role of BRD4 expression in high-grade serous ovarian Cancer","volume":"16","author":"Andrikopoulou","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.109097_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114205","article-title":"Therapeutic strategies to overcome cisplatin resistance in ovarian cancer","volume":"232","author":"Song","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0560","first-page":"15","article-title":"Cereblon-recruiting PROTACs: will new drugs have to face old challenges?","author":"Cie\u015blak","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109097_bb0565","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.1021\/acs.jmedchem.4c00015","article-title":"Recent Progress in DNA damage response-targeting PROTAC degraders","volume":"67","author":"Cheng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0570","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2022.08.048","article-title":"Accelerating PROTAC drug discovery: establishing a relationship between ubiquitination and target protein degradation","volume":"628","author":"Gross","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.109097_bb0575","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.bioorg.2025.109097_bb0580","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14789450.2024.2406785","article-title":"Cellular thermal shift assay: an approach to identify and assess protein target engagement","volume":"21","author":"Zhang","year":"2024","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.bioorg.2025.109097_bb0585","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-4939-8891-4_3","article-title":"Quantitative, real-time measurements of intracellular target engagement using energy transfer","volume":"1888","author":"Robers","year":"2019","journal-title":"Methods Mol. Biol. (Clifton, NJ)"},{"key":"10.1016\/j.bioorg.2025.109097_bb0590","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kipps","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109097_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.101939","article-title":"Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells","volume":"44","author":"Carmi","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0600","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1039\/D3NR06059D","article-title":"Nano-PROTACs: state of the art and perspectives","volume":"16","author":"Zhong","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.bioorg.2025.109097_bb0605","article-title":"Options to improve the action of PROTACs in Cancer: development of controlled delivery nanoparticles","volume":"9","author":"Juan","year":"2021","journal-title":"Front. Cell Develo. Biol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.119126","article-title":"Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer","volume":"338","author":"Zhou","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0615","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.2147\/IJN.S274289","article-title":"Endocytosis and organelle targeting of nanomedicines in Cancer therapy","volume":"15","author":"Wang","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioorg.2025.109097_bb0620","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for Cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater. (Deerfield Beach, Fla)"},{"key":"10.1016\/j.bioorg.2025.109097_bb0625","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12951-021-01100-2","article-title":"Nanomedicine for increasing the oral bioavailability of cancer treatments","volume":"19","author":"Parodi","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0630","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jconrel.2020.11.032","article-title":"Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles","volume":"330","author":"Chen","year":"2021","journal-title":"J. Controlled Release: Off. J Controlled Release Soc."},{"key":"10.1016\/j.bioorg.2025.109097_bb0635","first-page":"OF1","article-title":"Ubiquitin-specific protease 6 (USP6) mRNA lipid nanoparticles ignite anti-tumor immunity and suppress tumorigenesis in Ewing sarcoma","author":"Chou","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.109097_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.144444","article-title":"Tumor-targeting and redox-responsive photo-cross-linked nanogel derived from multifunctional hyaluronic acid-lipoic acid conjugates for enhanced in vivo protein delivery","volume":"314","author":"Sun","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0645","first-page":"25","article-title":"Targeted Nanocarrier-based drug delivery strategies for improving the therapeutic efficacy of PARP inhibitors against ovarian Cancer","author":"Gralewska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109097_bb0650","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202202103R","article-title":"Identification of the hub genes in polycystic ovary syndrome based on disease-associated molecule network","volume":"37","author":"Wu","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.bioorg.2025.109097_bb0655","doi-asserted-by":"crossref","first-page":"12003","DOI":"10.1080\/21655979.2021.2002494","article-title":"Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (TOP2A)","volume":"12","author":"Zhou","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.bioorg.2025.109097_bb0660","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2254012","article-title":"Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues","volume":"38","author":"Pichlak","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109097_bb0665","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/GRF.0000000000000896","article-title":"Genetic implications for Cancer management: the changing landscape of poly (ADP-ribose) polymerase inhibitor indications in the treatment of ovarian Cancer","volume":"67","author":"Walsh","year":"2024","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103984","article-title":"Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights","volume":"9","author":"Tuninetti","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bioorg.2025.109097_bb0675","series-title":"Investigation of a Novel PARP Inhibitor PET Tracer in Ovarian Carcinoma","author":"Simpkins","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109097_bb0680","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the Management of Ovarian Cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0685","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1080\/14796694.2025.2513848","article-title":"Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer","volume":"21","author":"Silverstein","year":"2025","journal-title":"Future Oncol. (London, England)"},{"key":"10.1016\/j.bioorg.2025.109097_bb0690","first-page":"14","article-title":"Estrogen receptor-\u03b1 targeting: PROTACs, SNIPERs, peptide-PROTACs, antibody conjugated PROTACs and SNIPERs","author":"Negi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109097_bb0695","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2018.05.012","article-title":"siRNA in ovarian cancer - delivery strategies and targets for therapy","volume":"283","author":"van den Brand","year":"2018","journal-title":"J. Controlled Release: Off. J. Controlled Release Soc."},{"key":"10.1016\/j.bioorg.2025.109097_bb0700","doi-asserted-by":"crossref","first-page":"113","DOI":"10.24976\/Discov.Med.202436180.10","article-title":"CircRNA Hsa_circ_0120175 promotes ovarian Cancer tumorigenesis and predicts a poor prognosis","volume":"36","author":"Xing","year":"2024","journal-title":"Discov. Med."},{"key":"10.1016\/j.bioorg.2025.109097_bb0705","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109097_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126635","article-title":"The safety and efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: a prospective cohort study","volume":"45","author":"Yang","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.bioorg.2025.109097_bb0715","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.bioorg.2025.109097_bb0720","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in Core components of E3 ligase complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.109097_bb0725","first-page":"2215","article-title":"Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway","volume":"14","author":"Ottis","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109097_bb0730","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825009770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825009770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:38:47Z","timestamp":1766057927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825009770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":146,"alternative-id":["S0045206825009770"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109097","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109097"}}